SHORT-TERM CHEMOTHERAPY REGIMEN OF MULTIDRUG-RESISTANT TUBERCULOSIS IN THE KYRGYZ REPUBLIC
Objective: To study the clinical course of tuberculosis (TB) with multiple drug resistance (MDR) in the treatment of short-term courses recommended by the WHO. Methods: Design of research - a retrospective study of 42 (100%) patients of both sexes aged 18-62 years who were on stationary and then in...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Avicenna Tajik State Medical University,
2018-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective: To study the clinical course of tuberculosis (TB) with multiple drug resistance (MDR) in the treatment of short-term courses recommended by the WHO. Methods: Design of research - a retrospective study of 42 (100%) patients of both sexes aged 18-62 years who were on stationary and then in outpatient treatment with short-term courses in 2017 and received a short course of chemotherapy for MDR TB (4-6 CmMfxPtoCfzZEH / 5 MfxPtoCfzZE) recommended by WHO. Results: According to the data on treatment outcomes, 4 (9.6%) of the patient because of the serious undesirable setting have been withdrawn from therapy. Out of 33 (78.6%) people with positive sputum test, smear conversion to negative was detected in 1 month already in half of the patients; of 99.2% of patients at the end of 3 months of chemotherapy, the destruction of pulmonary parenchyma persisted in 66.7% of patients. A favorable outcome of therapy was achieved in 73.8%, an unfavorable outcome occurred in 7.1% of cases. 3 (7.1%) of the patient fell out of sight, and 2 (4.8%) patients still continue treatment. Conclusion: The question of the efficacy of treatment with a short course of chemotherapy in Kyrgyzstan remains open, more objective answers will be given after a long detailed and voluminous analysis of the research conducted. Quite optimistic preliminary results obtained by us, we can say that a shorter duration of treatment will allow access to a more likely effective treatment, so as to reduce the high moment rates of portability treatment in patients. Although it is necessary to further confirm the effectiveness of these expectations it should not listen to the obstacle to the implementation of WHO recommendations. |
|---|---|
| Item Description: | 10.25005/2074-0581-2018-20-2-3-212-217 2074-0581 2959-6327 |